Hypertension Management with Additional Agents

Clinical Context and Treatment Algorithm

The European Society of Cardiology recommends adding a calcium channel blocker (amlodipine 5-10 mg daily) or a thiazide/thiazide-like diuretic (hydrochlorothiazide 12.5-25 mg or chlorthalidone 12.5-25 mg daily) as the third agent to achieve guideline-recommended triple therapy for patients with stage 2 hypertension 1, 2
For patients already on beta-blockers, the combination of beta-blocker + calcium channel blocker provides complementary mechanisms (heart rate control plus vasodilation), making amlodipine 5 mg once daily the preferred initial add-on 1, 2
The European Heart Journal suggests that chlorthalidone is preferred over hydrochlorothiazide due to its longer duration of action and superior outcomes data 2
The combination of beta-blocker + diuretic has decades of evidence supporting cardiovascular risk reduction 1

The European Society of Cardiology states that beta-blockers are not first-line agents for uncomplicated hypertension and should be combined with other major drug classes rather than dose-escalated alone 1
Adding a different mechanism of action is more effective than increasing the same drug class 1, 2
Target blood pressure is 120-129 mmHg systolic if well tolerated, or at minimum <140/90 mmHg 1

The European Heart Journal recommends adding an ACE inhibitor or ARB to create a four-drug regimen (beta-blocker + CCB + diuretic + RAS blocker) if blood pressure remains uncontrolled on triple therapy 1, 2
Alternatively, if already on three drugs at optimal doses, spironolactone 25-50 mg daily is the preferred fourth-line agent for resistant hypertension 2

The European Heart Journal advises against giving additional IV labetalol without adding oral maintenance therapy, as this only provides temporary control without addressing the underlying treatment gap 3
The European Society of Cardiology recommends against delaying adding a second oral agent in a patient with stage 2 hypertension (BP >160/100 mmHg), as prompt intensification reduces cardiovascular risk 1, 2
The European Heart Journal suggests avoiding combining two RAS blockers (ACE inhibitor + ARB) if you later add one, as this increases adverse events without benefit 1